S. Ferraciolli

Real-World Challenges in the MRI Detection and Classification of Amyloid-Related Imaging Abnormalities.

Anti-amyloid monoclonal antibody therapies (AATs) are increasingly used for the treatment of early symptomatic Alzheimer disease. Safe implementation of AATs relies on accurate assessment for exclusionary findings on baseline brain MRI and reliable longitudinal detection of amyloid-related imaging abnormalities (ARIA),...